A comparative analysis between automated assay and neutralization (or a surrogate, such as a viral reporter assay) is critical to avoid the distribution of low-titer CP that could later be shown to be ineffective (i.e., as occurred in the early compassionate and investigational uses of CP for COVID-19). Here, CP is linked to COVID-19.